Intelligence Profile
Science
The compound "AAV9-Follistatin" involves using an adeno-associated virus vector (AAV9) to deliver the follistatin gene into the body. The primary goal of this therapy is to enhance muscle mass and function, especially in the context of age-related muscle loss.
Molecular Mechanism:
Gene Delivery: AAV9 serves as a vector to introduce the follistatin gene into target cells. AAV9 is chosen for its efficiency in targeting muscle cells and minimal immune response.
Follistatin Expression: Once inside the muscle cells, the follistatin gene is transcribed and translated into the follistatin protein.
Myostatin Inhibition: Follistatin acts as a potent inhibitor of myostatin, a protein that restricts muscle growth. By binding to myostatin, follistatin prevents it from interacting with its receptor, allowing for increased muscle protein synthesis and growth.
Muscle Growth Promoter: The overall result is enhanced muscle growth and improved muscle function due to the reduction in myostatin activity.
Physiological Level:
- The combined therapy mentioned in the trial (NCT07443826) also includes a VEGF plasmid. VEGF (Vascular Endothelial Growth Factor) enhances blood supply and angiogenesis, potentially improving nutrient delivery and further supporting muscle health.
The clinical trial status is currently in Phase 1 and Phase 2, which suggests ongoing evaluation of safety, dosage, and initial efficacy.
Disclaimer: This information is for educational purposes only and not for medical advice. Always consult healthcare professionals for medical concerns.